Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Clinical trial NCT07225439 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07225439
Sponsor: Paolo Caimi, MD
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Non Hodgkin Lymphoma B-cell Non Hodgkin Lymphoma Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Primary Mediastinal Large B Cell Lymphoma Follicular Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Marginal Zone Lymphoma Mantle Cell Lymphoma

Start date: 2026-09-01
Primary completion: 2027-12-01
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.